Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology.

Carlo Salvarani, Nicolò Pipitone, Antonio Marchesoni, Fabrizio Cantini, Alberto Cauli, Ennio Lubrano, Leonardo Punzi, Raffaele Scarpa, Antonio Spadaro, Marco Matucci-Cerinic, Ignazio Olivieri, Society for Rheumatology Italian Society for Rheumatology

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

To update the 2006 Italian Society for Rheumatology recommendations for the use of biologic (TNF-α blocking) agents in the treatment of psoriatic arthritis (PsA). A panel of experts performed a literature search and identified the items that required updating on the basis of new published data. A draft of the updated recommendations was circulated to a group of Italian Rheumatologists with a specific expertise in PsA and in therapy with biologic agents, and their suggestions were incorporated in the final version. A consensus was achieved regarding the initiation and the monitoring of anti-TNF-α agents in PsA. Inclusion and exclusion criteria were defined and specific recommendations were made for patients with psoriatic peripheral synovitis, spondylitis, enthesitis, and dactylitis, respectively. We also specified criteria for assessment of response to treatment and for withholding and withdrawal of therapy. These recommendations may be used for guidance in deciding which patients with PsA should receive biologic therapy. Further updates of these recommendations may be published on the basis of the results of new clinical studies and of data from post-marketing surveillance.

Original languageEnglish
JournalClinical and Experimental Rheumatology
Volume29
Issue number3 Suppl 66
Publication statusPublished - May 2011

Fingerprint

Psoriatic Arthritis
Biological Therapy
Rheumatology
Spondylitis
Withholding Treatment
Synovitis
Biological Factors
Therapeutics
Marketing

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Salvarani, C., Pipitone, N., Marchesoni, A., Cantini, F., Cauli, A., Lubrano, E., ... Italian Society for Rheumatology, S. F. R. (2011). Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clinical and Experimental Rheumatology, 29(3 Suppl 66).

Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis : update from the Italian Society for Rheumatology. / Salvarani, Carlo; Pipitone, Nicolò; Marchesoni, Antonio; Cantini, Fabrizio; Cauli, Alberto; Lubrano, Ennio; Punzi, Leonardo; Scarpa, Raffaele; Spadaro, Antonio; Matucci-Cerinic, Marco; Olivieri, Ignazio; Italian Society for Rheumatology, Society for Rheumatology.

In: Clinical and Experimental Rheumatology, Vol. 29, No. 3 Suppl 66, 05.2011.

Research output: Contribution to journalArticle

Salvarani, C, Pipitone, N, Marchesoni, A, Cantini, F, Cauli, A, Lubrano, E, Punzi, L, Scarpa, R, Spadaro, A, Matucci-Cerinic, M, Olivieri, I & Italian Society for Rheumatology, SFR 2011, 'Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology.', Clinical and Experimental Rheumatology, vol. 29, no. 3 Suppl 66.
Salvarani, Carlo ; Pipitone, Nicolò ; Marchesoni, Antonio ; Cantini, Fabrizio ; Cauli, Alberto ; Lubrano, Ennio ; Punzi, Leonardo ; Scarpa, Raffaele ; Spadaro, Antonio ; Matucci-Cerinic, Marco ; Olivieri, Ignazio ; Italian Society for Rheumatology, Society for Rheumatology. / Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis : update from the Italian Society for Rheumatology. In: Clinical and Experimental Rheumatology. 2011 ; Vol. 29, No. 3 Suppl 66.
@article{bd8766df39fa4b85ac8e4b958b378ce4,
title = "Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology.",
abstract = "To update the 2006 Italian Society for Rheumatology recommendations for the use of biologic (TNF-α blocking) agents in the treatment of psoriatic arthritis (PsA). A panel of experts performed a literature search and identified the items that required updating on the basis of new published data. A draft of the updated recommendations was circulated to a group of Italian Rheumatologists with a specific expertise in PsA and in therapy with biologic agents, and their suggestions were incorporated in the final version. A consensus was achieved regarding the initiation and the monitoring of anti-TNF-α agents in PsA. Inclusion and exclusion criteria were defined and specific recommendations were made for patients with psoriatic peripheral synovitis, spondylitis, enthesitis, and dactylitis, respectively. We also specified criteria for assessment of response to treatment and for withholding and withdrawal of therapy. These recommendations may be used for guidance in deciding which patients with PsA should receive biologic therapy. Further updates of these recommendations may be published on the basis of the results of new clinical studies and of data from post-marketing surveillance.",
author = "Carlo Salvarani and Nicol{\`o} Pipitone and Antonio Marchesoni and Fabrizio Cantini and Alberto Cauli and Ennio Lubrano and Leonardo Punzi and Raffaele Scarpa and Antonio Spadaro and Marco Matucci-Cerinic and Ignazio Olivieri and {Italian Society for Rheumatology}, {Society for Rheumatology}",
year = "2011",
month = "5",
language = "English",
volume = "29",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "3 Suppl 66",

}

TY - JOUR

T1 - Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis

T2 - update from the Italian Society for Rheumatology.

AU - Salvarani, Carlo

AU - Pipitone, Nicolò

AU - Marchesoni, Antonio

AU - Cantini, Fabrizio

AU - Cauli, Alberto

AU - Lubrano, Ennio

AU - Punzi, Leonardo

AU - Scarpa, Raffaele

AU - Spadaro, Antonio

AU - Matucci-Cerinic, Marco

AU - Olivieri, Ignazio

AU - Italian Society for Rheumatology, Society for Rheumatology

PY - 2011/5

Y1 - 2011/5

N2 - To update the 2006 Italian Society for Rheumatology recommendations for the use of biologic (TNF-α blocking) agents in the treatment of psoriatic arthritis (PsA). A panel of experts performed a literature search and identified the items that required updating on the basis of new published data. A draft of the updated recommendations was circulated to a group of Italian Rheumatologists with a specific expertise in PsA and in therapy with biologic agents, and their suggestions were incorporated in the final version. A consensus was achieved regarding the initiation and the monitoring of anti-TNF-α agents in PsA. Inclusion and exclusion criteria were defined and specific recommendations were made for patients with psoriatic peripheral synovitis, spondylitis, enthesitis, and dactylitis, respectively. We also specified criteria for assessment of response to treatment and for withholding and withdrawal of therapy. These recommendations may be used for guidance in deciding which patients with PsA should receive biologic therapy. Further updates of these recommendations may be published on the basis of the results of new clinical studies and of data from post-marketing surveillance.

AB - To update the 2006 Italian Society for Rheumatology recommendations for the use of biologic (TNF-α blocking) agents in the treatment of psoriatic arthritis (PsA). A panel of experts performed a literature search and identified the items that required updating on the basis of new published data. A draft of the updated recommendations was circulated to a group of Italian Rheumatologists with a specific expertise in PsA and in therapy with biologic agents, and their suggestions were incorporated in the final version. A consensus was achieved regarding the initiation and the monitoring of anti-TNF-α agents in PsA. Inclusion and exclusion criteria were defined and specific recommendations were made for patients with psoriatic peripheral synovitis, spondylitis, enthesitis, and dactylitis, respectively. We also specified criteria for assessment of response to treatment and for withholding and withdrawal of therapy. These recommendations may be used for guidance in deciding which patients with PsA should receive biologic therapy. Further updates of these recommendations may be published on the basis of the results of new clinical studies and of data from post-marketing surveillance.

UR - http://www.scopus.com/inward/record.url?scp=80055095434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055095434&partnerID=8YFLogxK

M3 - Article

C2 - 21906425

AN - SCOPUS:80055095434

VL - 29

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 3 Suppl 66

ER -